Allogene Therapeutics (ALLO) stock forecast for 2026. Forecast tables and graphs.







Understanding Accounting and Bookkeeping Services for Business Success

June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success

Every successful business relies on accurate financial records. From managing cash flow to ensuring compliance with tax regulations, reliable accounting and bookkeeping services…
How much does a Turkish passport cost?

May 27, 2025 How much does a Turkish passport cost?

Turkish citizenship comes with numerous benefits. Once granted, a foreigner can enter 126 countries visa-free, enjoy high-quality healthcare and favorable tax regimes, and…
How Measurement and Mix Modeling Drive Better Business Decisions

May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions

In today’s data-driven business landscape, the ability to accurately measure and optimize marketing efforts has become a critical competitive advantage. As marketing evolves,…
Are you making these mistakes when analyzing candlestick patterns?

May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?

Trading is a very popular endeavor these days, and for good reason, as it is widely accessible and allows individuals to generate additional…
Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency

April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency

What defines a successful crypto expert? The amount of money earned, the number of luxury cars and international real estate? The presence of…

Allogene Therapeutics (ALLO) stock forecast for 2026

Updated: May 31, 2025 (09:43)

Sector: Healthcare

The share price of Allogene Therapeutics, Inc. (ALLO) now

What analysts predict: $8.2
52-week High/Low: $3.78 / $0.862

50/200 Day Moving Average: $1.39 / $2.093

This figure corresponds to the Average Price over the previous 50/200 days. For Allogene Therapeutics stocks, the 50-day moving average is the resistance level today.

For Allogene Therapeutics stocks, the 200-day moving average is the resistance level today.

Are you interested in Allogene Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Allogene Therapeutics stock price in 2026. How much will one Allogene Therapeutics share be worth in 2026? Is it worth taking profit / loss on ALLO stock now or waiting? What are analysts' forecasts for Allogene Therapeutics stock?

We forecast Allogene Therapeutics stock performance using neural networks based on historical data on ALLO stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.

Allogene Therapeutics, Inc. stock forecasts are adjusted once a day based on the closing price of the previous trading day.

The minimum target price for Allogene Therapeutics analysts is $8.2. Today 200 Day Moving Average is the resistance level (2.093 $). 50 Day Moving Average is the support level (1.39 $).




Historical and forecast chart of Allogene Therapeutics, Inc. stock

The chart below shows the historical price of Allogene Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the ALLO stock price can be found in the table below.


Allogene Therapeutics, Inc. operates as a biotechnology company. The Company develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. Allogene Therapeutics serves patients in the State of California.

Official site of the company

Trending Themes in the Healthcare Sector

Allogene Therapeutics (ALLO) Forecast for 2026

Month Target Pes. Opt. Vol., %
Jan 1.20 1.13 1.24 8.86 %
Mar 1.18 1.15 1.26 8.64 %
Mar 1.13 1.10 1.17 5.62 %
May 1.10 1.06 1.15 7.21 %
May 1.12 1.06 1.18 9.71 %
Jul 1.23 1.16 1.33 12.91 %
Jul 1.36 1.30 1.45 10.10 %
Aug 1.30 1.25 1.35 7.31 %
Oct 1.39 1.34 1.44 7.07 %
Oct 1.47 1.41 1.55 9.29 %
Dec 1.55 1.46 1.63 10.55 %
Dec 1.70 1.66 1.73 4.40 %

Allogene Therapeutics information and performance

Allogene Therapeutics Address

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, US

Market Capitalization: 258 103 000 $

Market capitalization of the Allogene Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ALLO shares in the company outstanding by the market price of one share.

EBITDA: -239 986 000 $

EBITDA of Allogene Therapeutics is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: None

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -1.22

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -1
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 3859.62

Enterprise Value (EV) /Revenue

EV To EBITDA: -1.039

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 218731000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Allogene Therapeutics price target for 2026 by month


Target values for the price of one Allogene Therapeutics share for Jan 2026.

The weighted average target price per Allogene Therapeutics share in Jan 2026 is: 1.20.
In Jan, the Positive dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 8.860% volatility is expected.
Pessimistic target level: 1.13
Optimistic target level: 1.24

Target values for the price of one Allogene Therapeutics share for Mar 2026.

The weighted average target price per Allogene Therapeutics share in Mar 2026 is: 1.18.
In Mar, the Negative dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 8.639% volatility is expected.
Pessimistic target level: 1.15
Optimistic target level: 1.26

Target values for the price of one Allogene Therapeutics share for Mar 2026.

The weighted average target price per Allogene Therapeutics share in Mar 2026 is: 1.13.
In Mar, the Negative dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 5.620% volatility is expected.
Pessimistic target level: 1.10
Optimistic target level: 1.17

Target values for the price of one Allogene Therapeutics share for May 2026.

The weighted average target price per Allogene Therapeutics share in May 2026 is: 1.10.
In May, the Negative dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 7.211% volatility is expected.
Pessimistic target level: 1.06
Optimistic target level: 1.15

Target values for the price of one Allogene Therapeutics share for May 2026.

The weighted average target price per Allogene Therapeutics share in May 2026 is: 1.12.
In May, the Positive dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 9.714% volatility is expected.
Pessimistic target level: 1.06
Optimistic target level: 1.18

Target values for the price of one Allogene Therapeutics share for Jul 2026.

The weighted average target price per Allogene Therapeutics share in Jul 2026 is: 1.23.
In Jul, the Positive dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 12.906% volatility is expected.
Pessimistic target level: 1.16
Optimistic target level: 1.33

Target values for the price of one Allogene Therapeutics share for Jul 2026.

The weighted average target price per Allogene Therapeutics share in Jul 2026 is: 1.36.
In Jul, the Positive dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 10.103% volatility is expected.
Pessimistic target level: 1.30
Optimistic target level: 1.45

Target values for the price of one Allogene Therapeutics share for Aug 2026.

The weighted average target price per Allogene Therapeutics share in Aug 2026 is: 1.30.
In Aug, the Negative dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 7.314% volatility is expected.
Pessimistic target level: 1.25
Optimistic target level: 1.35

Target values for the price of one Allogene Therapeutics share for Oct 2026.

The weighted average target price per Allogene Therapeutics share in Oct 2026 is: 1.39.
In Oct, the Positive dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 7.074% volatility is expected.
Pessimistic target level: 1.34
Optimistic target level: 1.44

Target values for the price of one Allogene Therapeutics share for Oct 2026.

The weighted average target price per Allogene Therapeutics share in Oct 2026 is: 1.47.
In Oct, the Positive dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 9.289% volatility is expected.
Pessimistic target level: 1.41
Optimistic target level: 1.55

Target values for the price of one Allogene Therapeutics share for Dec 2026.

The weighted average target price per Allogene Therapeutics share in Dec 2026 is: 1.55.
In Dec, the Positive dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 10.551% volatility is expected.
Pessimistic target level: 1.46
Optimistic target level: 1.63

Target values for the price of one Allogene Therapeutics share for Dec 2026.

The weighted average target price per Allogene Therapeutics share in Dec 2026 is: 1.70.
In Dec, the Positive dynamics for Allogene Therapeutics, Inc. shares will prevail with possible monthly volatility of 4.403% volatility is expected.
Pessimistic target level: 1.66
Optimistic target level: 1.73



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.